Full-Time
Senior Manager, Talent and Performance Platforms
Updated on 9/10/2026
Amgen
10,001+ employees
Biotech company creating biologic medicines
No salary listed
Hyderabad, Telangana, India
In Person
 People & HR (1) |
|---|
Get referred to Amgen
See people who can refer or advise you
- Experience designing, implementing, optimizing, and governing global Talent and Performance systems, platforms, processes, and operating models.
- Ability to translate Talent and Performance philosophies into scalable global processes, technology solutions, and employee experiences.
- Experience serving as a business product owner for Talent and Performance capabilities across Workday, Eightfold, artificial intelligence-enabled solutions, and other talent technologies.
- Ability to develop strategic product roadmaps balancing business priorities, user needs, technology opportunities, and operational excellence.
- Experience partnering with HR Technology, Digital, and external vendors to design, configure, test, implement, and enhance Talent solutions.
- Knowledge of automation, artificial intelligence, advanced analytics, emerging technologies, enterprise architecture, and governance standards.
- Experience leading global Performance Management, Talent Reviews, Succession Planning, Talent Marketplace, and related strategic Talent capabilities.
- Experience developing scalable operating models and leading cross-functional initiatives involving planning, governance, risk management, stakeholder engagement, user adoption, and organizational outcomes.
- Ability to establish priorities, operating rhythms, performance expectations, governance, documentation, and quality standards for sustainable global execution.
- Experience building partnerships across HR Business Partners, Organizational Effectiveness, HR Operations, Talent Acquisition, Learning, HR Technology, Digital, HR Analytics, and business leadership.
- Experience leading communication, training, and change management efforts for adoption of new capabilities and ways of working.
- Ability to define success measures and use workforce data, employee feedback, system metrics, operational data, and external benchmarks to evaluate effectiveness and drive improvement.
- Experience managing vendor relationships and external partners supporting Talent and Performance technologies and services.
- Partner with Talent Strategy leaders to translate Talent and Performance philosophies into scalable global processes, technology solutions, and employee experiences.
- Contribute operational, technology, and user experience insights to the evolution of Talent and Performance practices.
- Ensure Talent and Performance solutions align with business priorities and deliver a consistent global employee and manager experience.
- Serve as the business product owner for Talent and Performance capabilities across Workday, Eightfold, artificial intelligence-enabled solutions, and future talent technologies.
- Develop and maintain the strategic roadmap for Talent and Performance products.
- Partner with HR Technology, Digital, and external vendors to design, configure, test, implement, and continuously enhance Talent solutions.
- Identify opportunities to modernize Talent and Performance through automation, artificial intelligence, advanced analytics, and emerging technologies.
- Evaluate new technologies and industry best practices to improve employee experience, manager effectiveness, and organizational outcomes.
- Ensure Talent platforms are scalable, intuitive, secure, and aligned with enterprise architecture and governance standards.
- Lead the design, deployment, governance, and continuous improvement of global Talent and Performance processes.
- Develop scalable operating models that enable global consistency while supporting evolving business needs.
- Drive cross-functional initiatives that improve process effectiveness, user adoption, and organizational outcomes.
- Ensure successful execution of global Talent and Performance initiatives through planning, governance, risk management, and stakeholder engagement.
- Provide strategic leadership to the India-based Talent and Performance leadership and team.
- Establish priorities, operating rhythms, and performance expectations aligned with enterprise objectives.
- Foster innovation, collaboration, accountability, continuous learning, and operational excellence.
- Coach and develop leaders while building organizational capability for future business needs.
- Build trusted partnerships across HR and business stakeholder groups.
- Influence enterprise decisions regarding Talent and Performance products, platforms, and user experience.
- Lead communication, training, and change management efforts supporting adoption of new capabilities and ways of working.
- Define success measures and leverage workforce data to evaluate Talent and Performance products and programs.
- Partner with HR Analytics to generate actionable insights for product enhancements and strategic decisions.
- Use employee feedback, system metrics, operational data, and external benchmarks to drive continuous improvement and innovation.
- Ensure Talent and Performance processes are scalable, compliant, and operationally efficient.
- Establish governance, documentation, and quality standards for sustainable global execution.
- Manage vendor relationships and external partners supporting Talent and Performance technologies and services.
Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.
Company Size
10,001+
Company Stage
IPO
Headquarters
Thousand Oaks, California
Founded
1980
Get referred to Amgen
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue rose 10% to $10.1 billion, and guidance increased to $38.2 billion-$39.4 billion.
- Repatha sales jumped 37% to $953 million in Q2 2026, with U.S. prescriptions up 50%.
- MariTide advanced through multiple Phase 3 studies in 2026, supporting a 2027 obesity catalyst.
What critics are saying
- Prolia sales fell 32% in Q2 2026 as biosimilars attack Amgen’s legacy cash cow.
- FDA proposed withdrawing Tavneos in April 2026, signaling regulatory risk from integrity and efficacy issues.
- Olpasiran now faces Novartis pelacarsen failure scrutiny; a negative 2028 OCEAN(a) readout would crush Lp(a) upside.
What makes Amgen unique
- Repatha, Evenity, and Uplizna diversify Amgen beyond one blockbuster, per August 2026 sales.
- MariTide targets quarterly or eight-week dosing, unlike Lilly and Novo Nordisk weekly injections.
- Amgen’s 2027 Hyderabad Science and Innovation Center expands AI-enabled drug discovery globally.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Professional Development Budget
Conference Attendance Budget
Company News
Amgen trades at $393 per share, representing a trailing multiple of 23.3 times adjusted earnings. The biotech faces declining sales from Prolia and XGEVA, down 33% year-over-year to $1.1 billion in Q2 2026, due to biosimilar competition. Six key growth medicines grew 26% year-over-year, accounting for nearly 70% of Q2 product sales. Analysts forecast the forward multiple at 17.0 times for fiscal 2026 and 16.1 times for 2027. However, consensus assumes expanding profit margins whilst Amgen increases spending. Non-GAAP research spending is set to grow in high single digits for 2026, funding nine Phase III trials for MariTide, its obesity treatment candidate. Management warned of meaningful operating expense increases in Q3 2026. The valuation depends on margin expansion materialising during this investment phase.
Amgen faces heightened scrutiny for its experimental heart drug olpasiran after rival Novartis's pelacarsen failed to reduce major cardiovascular events in a Phase 3 trial, despite successfully lowering lipoprotein(a) levels. The setback demonstrates that improving laboratory biomarkers may not translate to better patient outcomes. Amgen's OCEAN(a) outcomes study has enrolled 7,297 participants and is tracking heart-related deaths and procedures over roughly five years. While olpasiran uses a different design and may target different patients, pelacarsen's failure removes assumptions about the commercial value of lowering Lp(a). Amgen's shares traded at $437.23, sitting 19.54% above its estimated fair value of $365.76. The company reported $10.1 billion in second-quarter revenue and $3.5 billion in free cash flow.
Jim Cramer highlighted Amgen's cholesterol drug Repatha as a key driver behind the company's 31% year-to-date rally, calling it an overlooked catalyst by Wall Street. The injectable treatment, administered every two weeks, reduces death risk by 20% in patients at high risk for heart attack or stroke. Repatha generated $953 million in second-quarter sales, up 37% year-over-year. US new prescriptions surged over 50%, split evenly between cardiologist use and primary-care adoption for high-risk patients. Cramer noted the drug works against diabetes and high cholesterol, though insurance reimbursement has posed challenges. Amgen trades at a forward PE of 19, compared to Eli Lilly's 32, whilst outperforming Lilly's 10% gain this year. Repatha is one of six growth drivers representing nearly 70% of Amgen's product sales. The company raised full-year revenue guidance to $38.2-$39.4 billion.
Amgen shares jumped 3.5% to $440.08 on Wednesday as healthcare stocks reached record highs. The biotech company reported second-quarter revenue of $10.1 billion, up 10%, whilst GAAP earnings surged 65% to $4.37 per share. Twenty-two of Amgen's medicines posted double-digit sales growth, with seventeen products generating over $1 billion in annualised sales. Six key growth products climbed 26% and now account for nearly 70% of product revenue. The rally came as investors rotated into healthcare following excitement around Merck and Moderna's melanoma breakthrough. However, Amgen now trades at a 19% premium to its fair value estimate of $365.04, putting pressure on execution as some products like Prolia face headwinds.
Amgen and Regeneron could benefit from surging demand for GLP-1 drugs, which traditionally treated diabetes but now address obesity and obstructive sleep apnea. Amgen's stock is up 27% this year, with second-quarter revenue rising 10% year-over-year to $10.1 billion. The company is testing MariTide, an investigational GLP-1 medicine, in phase 3 studies for weight management and diabetes. MariTide could be administered monthly or less frequently, offering a convenience advantage over current daily or weekly treatments. Regeneron is also positioned to capitalise on the GLP-1 market expansion. Both companies present alternatives to current market leaders Eli Lilly and Novo Nordisk for investors seeking exposure to the growing GLP-1 drug category.